Valuation: Evotec SE

Market Cap 60Cr 70Cr 56Cr 51Cr 96Cr 6.66TCr 97Cr 659.44Cr 257.16Cr 3.35TCr 261.49Cr 255.8Cr 11TCr P/E 2026 *
-2.86x
P/E 2027 * -7.8x
Enterprise Value 74Cr 86Cr 69Cr 63Cr 118.85Cr 8.26TCr 120.42Cr 817.36Cr 318.75Cr 4.15TCr 324.11Cr 317.05Cr 14TCr EV / Sales 2026 *
1.23x
EV / Sales 2027 * 1.05x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 week-2.61%
Current month-1.58%
1 month-3.06%
3 months-35.83%
6 months-45.02%
Current year-38.42%
1 week 3.26
Extreme 3.258
3.47
1 month 3.26
Extreme 3.258
3.88
Current year 3.18
Extreme 3.176
6.73
1 year 3.18
Extreme 3.176
7.3
3 years 3.18
Extreme 3.176
23.44
5 years 3.18
Extreme 3.176
45.83
10 years 3.18
Extreme 3.176
45.83
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Date Insider Type Main position Quantity % Market Cap.
30/01/26 Fiscal year

Chief Technology Officer

6,760 0.0038%
30/01/26 Tax

Chief Technology Officer

3,653 0.0021%
09/12/25 Buy

Chairman

20,000 0.0113%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.61%-45.13%-83.58% 70Cr
+1.09%+5.26%+4.52%+26.24% 5.16TCr
-1.07%+2.82%+465.96%+586.75% 4.49TCr
+1.47%+9.79%+35.92%+21.40% 4.28TCr
+1.44%+7.77%+19.38%+92.75% 4.26TCr
-0.93%-4.33%+16.18%+53.76% 3.18TCr
+1.32%+7.30%+33.89%+150.10% 1.73TCr
-0.60%+1.93% - - 1.66TCr
+0.03%+3.41%+6.55%+32.10% 1.48TCr
+1.28%+5.41%+82.40%+47.43% 1.41TCr
Average +0.40%+3.73%+68.85%+103.00% 2.77TCr
Weighted average by Cap. +0.48%+4.70%+99.19%+145.68%

Financials

2026 *2027 *
Net sales 60Cr 70Cr 56Cr 51Cr 96Cr 6.7TCr 98Cr 662.92Cr 258.52Cr 3.36TCr 262.87Cr 257.15Cr 11TCr 72Cr 84Cr 67Cr 62Cr 115.6Cr 8.03TCr 117.13Cr 795.05Cr 310.04Cr 4.04TCr 315.26Cr 308.4Cr 13TCr
Net income -24Cr -28Cr -22Cr -20Cr -38Cr -2.63TCr -38Cr -260.71Cr -101.67Cr -1.32TCr -103.38Cr -101.13Cr -4.38TCr -6.04Cr -7.05Cr -5.65Cr -5.17Cr -9.7Cr -674.33Cr -9.83Cr -67Cr -26Cr -338.75Cr -26Cr -26Cr -1.12TCr
Net Debt 14Cr 17Cr 13Cr 12Cr 23Cr 1.6TCr 23Cr 157.92Cr 62Cr 801.54Cr 63Cr 61Cr 2.65TCr 16Cr 19Cr 15Cr 14Cr 26Cr 1.81TCr 26Cr 179.27Cr 70Cr 909.92Cr 71Cr 70Cr 3.01TCr
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
21/26/21 €3.356 0.00% 3,12,228
20/26/20 €3.356 -1.41% 6,32,201
19/26/19 €3.404 +2.53% 6,85,015
18/26/18 €3.320 -3.26% 8,23,422
17/26/17 €3.432 -0.41% 7,36,711
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
3.356EUR
Average target price
4.586EUR
Spread / Average Target
+36.64%

Quarterly revenue - Rate of surprise